These studies illustrate that while the role of OSM and OSMRβ in bladder cancer has yet to be fully elucidated, OSMRβ allele variants may serve as a biomarker prognosis test for patients with bladder cancer, and therapeutics targeting OSMRβ may be a beneficial target for bladder cancer patients. This evidence concerns the gene OSM and urinary bladder cancer.